SSKN STRATA Skin Profit After Tax

Corporate emblem and logo of STRATA Skin Sciences (SSKN)

STRATA Skin Sciences is implementing advanced laser developments for the targeted therapy of dermatological pathologies. Exclusive XTRAC patents enable the effective treatment of vitiligo and psoriasis without medication. A stable cash flow from equipment sales ensures business autonomy. The company's profit chart visualizes the stability of financial corridors, where the -0.01 level is the current metric determining the issuer's market strength.

Net Income: STRATA Skin Sciences, Inc. (SSKN) for 07/04/2022 - 02/21/2026

Financial and market metric breakdowns for strataskinsciences.com (SSKN)

- market value and analyst target forecast:
Stock Price STRATA Skin Sciences, Inc.|SSKN - Price Target Chart
- market capitalization data:
Market Valuation STRATA Skin Sciences, Inc.|SSKN - Enterprise Value
- issuer book value statistics:
Net Asset Value per Share STRATA Skin Sciences|SSKN - Company Net Assets|Market Capitalization to Book Value Ratio strataskinsciences.com|SSKN - Cumulative Company Assets
- debt burden and liquidity indicators:
Aggregate Debt to Capital STRATA Skin Sciences|SSKN - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient STRATA Skin Sciences, Inc.|SSKN - Company Aggregate Debts|Debt to Book Value STRATA Skin Sciences, Inc.|SSKN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings STRATA Skin Sciences|Quick Liquidity Indicator strataskinsciences.com
- company profitability and valuation multiples indicators:
SSKN - Net Profit
Fundamental valuation:SSKN, STRATA Skin
Flagship merchandise of STRATA Skin

A steady stream of payments from the maintenance of laser psoriasis treatment systems provides a robust operational foundation that directly impacts the balance sheet profits of STRATA Skin Sciences (SSKN). This indicator captures the real-time reaction of net income to shifting market multiples and the rigidity of Fed policy, allowing investors to assess the actual resilience of SSKN assets against industry downturns through daily cash flow dynamics.

Key competitors

Dexcom CGM (DXCM) - Net Profit|Company Net Income Penumbra, Inc.|novanta.com - Profit After Tax|Net Profit HAE|INSP - Company Net Income|PROCEPT BioRobotics Inc - Net Income|Net Profit CONMED Inc. CNMD|PLSE: Net Income|inmodemd.com - Profit After Payment of Taxes|PMI: Net Profit|SRDX - Net Financial Result|SENS (Senseonics Holdings) - Net Profit|Net Income NeuroPace Medical (NPCE)|Net Income TCMD (Tactile Systems Technology)|SNWV (sanuwave.com) - Final Profit|Company Net Income Outset Medical OM|ELMD - Net Income|LENSAR, Inc - Net Profit|Company Net Income AVITA Medical Inc|PROF: Net Profit|Company Profit BDMD|EDAP (EDAP TMS SA) - Net Profit|Bovie Medical (APYX) - Net Financial Result|Net Profit ICCM|Net Income pulmonx.com LUNG|Net Profit TELA (TELA Bio)|Net Profit CytoSorbents Corp CTSO|SRTS - Company Net Income|ZYXI: Company Net Income|ECOR (electrocore.com) - Net Income|Vicarious Surgical - Final Profit|IINN (Inspira Technologies Oxy B.H.N. Ltd.) - Net Profit|Company Net Income seastarmedical.com ICU|Company Net Income IRIDEX Corporation (IRIX)|ibs.inc (INBS) - Annual Net Income|Beyond Air - Net Income|Net Profit Profusa, Inc PFSA|GlucoTrack - Net Profit|Net Financial Result NanoVibronix Inc. NAOV|Venus Concept (VERO) - Company Net Income|Profit After Tax NUWE (Nuwellis Inc)|Company Net Income Aethlon|Net Income TransEnterix (ASXC)|Net Profit AVGR|BSGM - Company Net Income|Company Net Income Cutera CUTR|KNW: Company Profit|NARI: Net Income|Nevro Medical - Profit After Payment of Taxes|reshapelifesciences.com (RSLS) - Company Net Income|SILK - Net Financial Result